Breast Biopsy Market Size, Share Global Analysis Report, 2022 – 2028

Industry Insights

[227+ Pages Report] According to Facts and Factors, the Global Breast Biopsy Market was valued at USD 702.13 million in 2021 and is predicted to increase at a CAGR of 7.3% to USD 1,109.35 million by 2028. The study examines the market in terms of revenue in each of the major regions, which are classified into countries. The report analyses the global breast biopsy market’s drivers and restraints, as well as the impact they have on-demand throughout the projection period. In addition, the report examines global opportunities in the breast biopsy market.

Market Overview

A breast biopsy is a diagnostic procedure used to determine whether or not a small sample of breast tissue removed is cancerous. It is regarded to be one of the most effective cancer detection methods. Although 70-80 percent of biopsies are cancer-free, they may show features that predispose them to breast carcinoma. A breast biopsy is recommended when a person has symptoms such as a breast lump, sore breast, breast dimpling, peeling of the breast, and nipple discharge. In recent years, the Breast Biopsy market has grown due to the increasing prevalence of breast cancer cases worldwide and the least invasive method.

Growth Drivers

The rising number of breast cancer cases has compelled governments around the world to promote awareness about the need for early detection, which is projected to drive market expansion. A liquid biopsy is a blood test that helps doctors find cancer cells (circulating tumor cells) or tumor DNA fragments in the blood. This approach eliminates the need for surgical and needle biopsies, allowing physicians to detect cancer in its early stages. Various players are now undertaking clinical trials to demonstrate the efficacy and efficiency of liquid biopsy in oncology; favorable results are likely to open up new prospects for market participants.

Biopsy needle treatments, such as core needle and fine needle procedures, help radiologists and surgeons examine anomalies at specific sites. Patients may become sick with these procedures, however, because they involve cuts and incisions to gather tissue samples. In many situations, biopsy needles are reused, increasing the risk of infection during these procedures. As a result, in order to prevent the danger of infection from these procedures, healthcare providers and patients may choose alternate diagnostic techniques for specific illnesses.

COVID – 19 Impact

The influence of the coronavirus epidemic and the ensuing lockdown may be seen in a variety of businesses, including the breast biopsy market. The implementation of new guidelines and regulations is stifling the expansion of this industry. Additionally, limited access to clinics, social isolation, and population lockdown, which results in a slowdown in patient flow and referrals, have all had an impact on market growth. Due to the broad development of COVID, several surgical plans have been postponed.

As surgical treatments raise the risk of infection, physicians have had to make difficult decisions to postpone elective surgery. Potential delays in cancer detection or treatment could result in life-threatening situations, which had to be balanced during the pandemic owing to the possibility of COVID infection. During the early stages of the pandemic, this was the most difficult obstacle to overcome.

Segmentation Analysis

The global Coconut Water market is segregated based on Product, Type, Guidance, and Application.

In terms of Guidance, the stereotactic breast biopsy is gaining a significant share in the forecast period. A stereotactic breast biopsy is a non-surgical procedure for determining a breast abnormality. Surgeons recommend surgery if the results of a stereotactic breast biopsy show the presence of malignant development. Low amounts of radiation are used in stereotactic needle breast biopsy to pinpoint the questionable spot. It eliminates many tissues in a single insertion while producing minimal pain. This less invasive procedure leaves little to no scarring and can help doctors spot tiny malignancies more quickly.

In terms of application, the primary use of breast biopsy methods is early diagnosis. A biopsy is a confirming test that allows for the early detection of cancer/tumor, resulting in faster recovery, extended longevity, and lower morbidity and death. A breast biopsy is recommended by doctors for the early identification of breast cancer. Various government and commercial organizations, market players, and hospitals are launching unique initiatives to improve public awareness of breast cancer and the clinical benefits of early detection through screening programs. These endeavors to raise awareness about the early detection and diagnosis of breast cancer are projected to fuel demand for breast biopsy devices, propelling market growth even further.

Report Scope

Regional Landscape

North America now dominates the market share, accounting for more of a major share in the forecast period. The advancement of medical infrastructure and technology has aided the region's overall industry growth. Additionally, rising awareness of palpable lumps in the breasts, early detection, and self-examination have all influenced the growth of the breast biopsy market. Breast Biopsy techniques have grown in popularity due to their minimally invasive diagnostic and simple processes.

Due to the limits imposed by pandemics, several sophisticated healthcare systems have obtained alternative therapeutic pathways. The region's biggest economies, particularly the United States and Canada, contribute significantly to the regional market value. The region offers a prospective medical tourism market, which contributes to the region's dominant regional market value.

Competitive Landscape

The report contains qualitative and quantitative research on the global Breast Biopsy Market, as well as detailed insights and development strategies employed by the leading competitors. The report also provides an in-depth analysis of the market's main competitors, as well as information on their competitiveness. The research also identifies and analyses important business strategies used by these main market players, such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts. The study examines, among other things, each company's global presence, competitors, service offers, and standards.

List of Key Players in the Global Breast Biopsy Market:

• Hologic, Inc. (US)
• Becton, Dickinson and Company (US)
• Danaher Corporation (US)
• Merit Medical Systems (US)
• Medtronic (Ireland)
• IZI Medical Products (US)
• Argon Medical (US)
• STERYLAB S.r.l. (Italy)
• Scion Medical Technologies, LLC (China)
• QIAGEN (Netherlands)
• Biocept Inc. (US)
• Bio-Rad Laboratories, Inc. (US)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Menarini Silicon Biosystems, Spa (Italy)
• Exact Sciences Corporation (US)
• Thermo Fisher Scientific, Inc. (US)
• Cardiff Oncology, Inc. (US)
• Myriad Genetics, Inc. (US)
• Illumina, Inc. (US)
• Fluxion Biosciences Inc (US)

The global breast biopsy market is segmented as follows:

By Product Segment Analysis

• Biopsy Needles
• Guidance Systems
• Biopsy Tables
• Localization Wires
• Assay Kits
• Liquid Biopsy Instruments
• Others

By Type Segment Analysis

• Needle Breast Biopsy
• Core Needle Biopsy (CNB)
• Fine Needle Aspiration Biopsy (FNAB)
• Vacuum-assisted Biopsy (VAB)
• Open Surgical Breast Biopsy
• Excisional
• Incisional
• Liquid Breast Biopsy
• Circulating Tumor Cells
• Circulating Tumor DNA (CtDNA)
• Other Biomarkers

By Guidance Segment Analysis

• Image-Guided Biopsy
• Mammography-guided Stereotactic Biopsy
• Ultrasound-guided Biopsy
• MRI-guided Biopsy
• Other Guidance Techniques
• Liquid Biopsy
• NGS-based Biopsy
• PCR-based Biopsy
• Microarray-based Biopsy

By Application Segment Analysis

• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic Countries
    • Denmark
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America